F.D.A.’s Approval of Drug for Autism Upends Review Process

Written by

in

The New York Times – Business:

The agency revived an old treatment for cancer patients, unilaterally approving it for a subset of people with autism. Experts worry that the narrower scope will get lost in the hype.

This post first appeared in The New York Times – Business. Read the original article.